This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Benedetti-Panici, P. Articles by Landoni, F. Search for Related Content PubMed PubMed Citation Articles by Benedetti-Panici, P. Articles by Landoni, F.

Neoadjuvant Chemotherapy and Radical Surgery Versus Exclusive Radiotherapy in Locally Advanced Squamous Cell Cervical Cancer: Results From the Italian Multicenter Randomized Study

From the Campus Bio-Medico Free University, Catholic University, and Regina Elena Institute, Rome; San Gerardo Hospital, University of Milan, and National Cancer Institute, Milan; University of Florence, Florence; National Cancer Institute, Naples; and University of Turin, Turin, Italy.

Address reprint requests to Pierluigi Benedetti-Panici, MD, University Campus Bio Medico, Via E Longoni, 8300155, Rome, Italy; email: p.panici{at}unicampus.it

PURPOSE: Neoadjuvant chemotherapy (NACT) and radical surgery (RS) have emerged as a possible alternative to conventional radiation therapy (RT) in locally advanced cervical carcinoma. In 1990, a phase III trial was undertaken to verify such a hypothesis in terms of survival and treatment-related morbidity.

PATIENTS AND METHODS: Patients with squamous cell, International Federation of Gynecology and Obstetrics stage IB2 to III cervical cancer were eligible for the study. They received cisplatin-based NACT followed by RS (type III to V radical hysterectomy plus systematic pelvic lymphadenectomy) (arm A) or external-beam RT (45 to 50 Gy) followed by brachyradiotherapy (20 to 30 Gy) (arm B).

RESULTS: Of 441 patients randomly assigned to NACT+RS or RT, eligibility was confirmed in 210 and 199 patients, respectively. Treatment was administered according to protocol in 76% of arm A patients and 72% of arm B patients. Adjuvant treatment was delivered in 48 operated patients (29%). There was no evidence for any significant excess of severe morbidity in one of the two arms. The 5-year overall survival (OS) and progression-free survival (PFS) rates were 58.9% and 55.4% for arm A and 44.5% and 41.3% for arm B (P = .007 and P = .02), respectively. Subgroup survival analysis shows OS and PFS rates of 64.7% and 59.7% (stage IB2-IIB, NACT+RS), 46.4% and 46.7% (stage IB2-IIB, RT) (P = .005 andP = .02), 41.6% and 41.9% (stage III, NCAT+RS), 36.7% and 36.4% (stage III, RT) (P = .36 and P = .29), respectively. Treatment had a significant impact on OS and PFS.

CONCLUSION: Although significant only for the stage IB2 to IIB group, a survival benefit seems to be associated with the NACT+RS compared with conventional RT.

This article has been cited by other articles:

				P. B. Panici, F. Bellati, N. Manci, M. Pernice, F. Plotti, V. Di Donato, M. Calcagno, M. A. Zullo, L. Muzii, and R. Angioli Neoadjuvant Chemotherapy Followed by Radical Surgery in Patients Affected by FIGO Stage IVA Cervical Cancer Ann. Surg. Oncol., September 1, 2007; 14(9): 2643 - 2648. [Abstract] [Full Text] [PDF]

				D. H. Moore Cervical Cancer Obstet. Gynecol., May 1, 2006; 107(5): 1152 - 1161. [Abstract] [Full Text] [PDF]

				A. Duenas-Gonzalez, C. Lopez-Graniel, A. Gonzalez-Enciso, L. Cetina, L. Rivera, I. Mariscal, G. Montalvo, E. Gomez, J. de la Garza, G. Chanona, et al. A phase II study of multimodality treatment for locally advanced cervical cancer: neoadjuvant carboplatin and paclitaxel followed by radical hysterectomy and adjuvant cisplatin chemoradiation Ann. Onc., August 1, 2003; 14(8): 1278 - 1284. [Abstract] [Full Text] [PDF]

				A. Duenas-Gonzalez, C. M. Lopez-Graniel, A. Mota, A. Mohar, P. Benedetti-Panici, and S. Greggi Neoadjuvant Chemotherapy Followed by Surgery in Locally Advanced Cervical Carcinoma J. Clin. Oncol., June 15, 2002; 20(12): 2908 - 2910. [Full Text] [PDF]